TICKERNERD
Menu
KLRSKLRSHealthcare · Biotechnology

KLRS Stock Forecast: Kalaris Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.99
−1.49% on the day

The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. hold a median 12-month price target of $20 — +905.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$48.1M
Ticker Nerd rank
23/ 100
Median analyst target
$20
Analysts covering
8
Revenue$0.0
Operating income−$12.4M
Net income−$11.5M
Free cash flow−$11.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.1%
1M
−38.6%
YTD
−76.4%
1Y
−54.6%
From 52W high
−81.9%
From 52W low
+4.2%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KLRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kalaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
23/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
82
Revisions
64
Volatility
62
Quality
50
Growth
33
Accruals
27
Issuance
16
Momentum
14
Value
9

Size (82): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KLRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KLRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26KLRSHigh $25Median $20Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $7Median $20High $25

The green dot is the last close — the median target sits +905.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 June 2026TD CowenInitiatesBuy—
14 May 2026WedbushInitiatesOutperform—
13 May 2026CitizensMaintainsMarket Outperform—
16 Apr 2026Morgan StanleyInitiatesOverweight—
23 Dec 2025Chardan CapitalInitiatesBuy—
3 Nov 2025CitizensInitiatesMarket Outperform—
3 Sept 2025Raymond JamesInitiatesStrong Buy—
8 Apr 2025William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KLRS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

KLRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Kalaris Therapeutics, Inc. returned −54.6% against +15.6% for the S&P 500, dividends included.

KLRS vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26KLRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KLRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Kalaris Therapeutics, Inc. (KLRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
1.0×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−79.9%

Higher than 16% of US stocks

Return on assets
−31.0%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kalaris Therapeutics, Inc. (KLRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kalaris Therapeutics, Inc. has a market value of $48.1M and an enterprise value of −$44.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$44.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$41.2M.

  • Shares outstanding: 23.8M.

  • Trailing P/E: −0.7×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kalaris Therapeutics, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

KLRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KLRSKalaris Therapeutics, Inc.$48.1M23
ANVSAnnovis Bio, Inc.$42.3M28
INMBINmune Bio, Inc.$42.8M49
ACETAdicet Bio, Inc.$43.0M37
GRCEGrace Therapeutics, Inc.$41.4M47
ATNMActinium Pharmaceuticals, Inc.$43.3M76
TVGNTevogen, Inc.$41.3M17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kalaris Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KLRS news & analysis

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 31 Aug 2026neutral

Kalaris Therapeutics announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company is developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.

Why it matters — A KLRS watcher would care because management's appearance at a major healthcare conference provides a platform to discuss the company's clinical-stage pipeline, including its lead candidate TH103.

FAQ

Frequently asked questions about KLRS stock

What is the KLRS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KLRS stock a buy right now?

Of the 8 analysts covering Kalaris Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kalaris Therapeutics, Inc. 23 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KLRS?

As at 21 Oct 2026, Kalaris Therapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).

Will KLRS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +905.0% from the last close, and Ticker Nerd's factor model ranks Kalaris Therapeutics, Inc. 23 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KLRS stock forecast for 2030?

No analyst covering Kalaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.

How has KLRS stock performed over the past year?

Kalaris Therapeutics, Inc. returned -54.6% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kalaris Therapeutics, Inc. do?

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs.

What is the latest news on KLRS?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference". Kalaris Therapeutics announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The company is developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.

Company

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs. The company’s lead program is TH103, an investigational anti-VEGF therapy designed for exudative and neovascular retinal conditions, including neovascular age-related macular degeneration. Kalaris Therapeutics also works on extending TH103’s use across other retinal disorders such as diabetic macular edema and retinal vein occlusion. Its current business centers on ophthalmology and biotechnology, where it aims to address sight-threatening diseases through targeted retinal therapies. The company is headquartered in the United States and operates as a specialist developer within the broader healthcare market.

CEO Mr. Andrew Oxtoby · 20 employees · United States · https://kalaristx.com